Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that it has entered into an antibody evaluation and option agreement with Neurocrine Biosciences Inc. The agreement grants Neurocrine Biosciences access to Biocytogen?s fully human antibodies against multiple specified targets, with an option to license selected antibodies for therapeutic product development, manufacturing and commercialization for all uses worldwide. Additional targets may be included under this agreement subject to mutual agreement. The antibodies were generated by Biocytogen?s proprietary RenMice platforms. Under the terms of the agreement, if options are exercised, Biocytogen will be entitled to option-exercise fees, development and commercialization milestone payments, as well as single-digit royalties on net sales for each selected target.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Equities
2315
CNE100005D27
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.89 CNY | +1.95% | -7.01% | -25.79% |
05-06 | Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies | CI |
04-26 | Biocytogen Pharmaceuticals' Loss Narrows in 2023 | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.79% | 454M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- 2315 Stock
- News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Biocytogen Pharmaceuticals Co., Ltd. Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences